ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Dear All (with thanks to Louise for co-authoring and with a wonkish alert ... settle in for the ride!),Today's newsletter discusses the intersection of three themes around antibiotic access. Recall first how the paper by Baraldi et al. (1 Dec 2024 newsletter) taught us that there are at least six variations to the idea of access that can be summarized as UNSLAP: (U)nregistered, (N)ever registered (or, non-registered), (S)hort-term shortage, (L)ong-term shortage, (A)ffordability, and (P)hysical Presence of a Health Care Pfacility.Thus, for example, the superb papers by Laxminarayan & colleagues about sustainable access in the sense of lack of infrastructure focus mainly on Affordability and Physical presence of healthcare infrastructure to deliver the drugs (see the 23 May 2024 newsletter entitled "Lancet: 10-20-30 targets to address AMR by 2030"). Note especially that the idea of "(P)hysical Presence of a Health Care Pfacility" covers the many challenges of connecting the patient with the drug and is sometimes called the "last mile problem" (excellent 27 May 2022 UN Trade & Development blog). It will need another newsletter!But for today, we need to move to the other end of the acronym and in particular, the supply chains that manufacture and deliver the antibiotics we expect to find on the...
Dear All (and with thanks...
Dear All,I wrote in the...
Dear All, Two quick updates...
Latest Government Action
Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year delays in access to new antibiotics were common even in high income countries (19 Aug 2021 newsletter with YouTube discussion). But as we'll learn today, that analysis considers only one possible facet of "lack of access." In an instructive new paper, Baraldi, Ardal, Aho, Popescu, and Melaku have given us a powerful new analytical framework showing that there are at least six (6!) possible meanings of "Lack of Access" to antibiotics (and see just before my signature a discussion of the UNSLAP acronym for same). Here are the links you need: The paper by Baraldi et al.: "The multifaceted nature of lack of access to antibiotics: types ofshortage and specific causes, consequences, and solutions" Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2024.11.012, 2024. A 2003 white paper summarizing indicators used as part of the Millennium Development Goals (MDGs), the predecessor to the current UN Sustainable Development Goals (SDGs): The white paper (the relevant text is on page 97) The MDG website The SDG website (the SDGs replaced the MDGs in 2015) Post-newsletter addendum: See also the 13 Dec 2024 newsletter...
Dear All, The Global Leaders Group on Antimicrobial...
Dear All,BARDA has released a...
Dear All, Greetings from Porto...
R&D Insight
Dear All: Here's a potpourri...
Dear All (and with thanks...
Dear All: Per an email...
Dear All: This is your...
(Updated on 8 July 2020)Dear...
Dear All, Supplementing and augmenting...
Dear All: Apologies for the...
Dear All: FDA has now posted a...
Dear All: Cassini et al....
Heads-up ... numerous changes in...
Dear All (wonkish alert ......
Can you help?
Dear All,I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City...
Dear All, Heads up! Having...
Note: Be sure to take...
Update on 11 October 2023: The...
Dear All,Along with more than...
Dear All (and with thanks to...
Dear All, Two items for...
Dear All, Three things today......
Dear All, Greetings from ECCMID...
Dear All,A key theme of...
Dear All,Following hard on the...
Dear All, A short one...
Dear All, We are swimming...
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
AMR Fireside Chats
1/18 videos
1
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
38:24
2
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
32:59
3
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
43:55
4
Episode 14 w/ Lynn Silver - AMR Fireside Chat
56:23
5
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
30:01
6
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
34:22
7
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
32:31
8
Episode 10 w/ Anna Govett - AMR Fireside Chat
14:54
9
Episode 9 w/ Fatema Rafiqi, PhD - AMR Fireside Chat
34:10
10
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
35:04
11
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
35:41
12
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
26:25
13
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
45:50
14
Episode 5 w/ Christine Årdal - AMR Fireside Chat
43:44
15
Episode 4 w/ Peter Beyer - AMR Fireside Chat
39:21
16
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
11:45
17
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
15:44
18
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
52:56
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Note: See also these related newsletters: 20 Feb 2020 (link) on DTR as part of the language of resistance and 7 June 2020 (link) on
Read More →
Draft EMA antibacterial guidance: Analysis
Dear All: I wrote previously that EMA posted an extensively updated and consolidated version of their previously separate Guideline (CPMP/EWP/558/95 Rev.2) and Addendum (EMA/CHMP/351889/2013) documents into a single draft
Read More →
Modeling the value of an effective antibiotic — Megiddo et al.
Dear All: I have previously written about the challenge of applying health technology assessment (HTA) to estimate the monetary value of an effective antibiotic: To my knowledge,
Read More →
FDA workshop: Insights on inhaled antifungals and antibacterials
Dear All (wonkish alert … coffee up!), FDA held a workshop on 25 Sep 2020 on development of inhaled antifungal (AF) therapies with a focus
Read More →
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress
Read More →
Scary, Scarier, Scariest (Part 2): What can YOU do about it?
Long note alert— apologies! Get a cup of coffee and settle in… Dear All: My 22 Apr 2019 note entitled Scary, Scarier, Scariest: Achaogen / FT
Read More →
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
Dear All (and heads-up for a rather lengthy and wonkish note … settle in for the details), Last week saw substantial AMR-related news released in
Read More →
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
Dear All (and with thanks to Kevin Outterson for substantial help with this newsletter), On August 2, 2019, the US government agency that administrates Medicare &
Read More →
UK to expand NHS Subscription Pilot! Consultation Period launches
Dear All (and with thanks to Kevin for co-authoring), The UK NHS England Pilot is known to us all as the first real attempt at an antibiotic
Read More →
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
Dear All (with thanks to Kevin as the lead author on this note and also with a wonkish note alert … refresh your coffee and
Read More →
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Dear All: FDA today hosted their eagerly awaited workshop on animal models in support of narrow-spectrum agents for A. baumannii (Abau) and P. aeruginosa (Pae). It was a really
Read More →
Plazomicin (Achaogen) financial post-mortem: #PassPASTEUR
Dear All (and with thanks to Kevin for co-authoring and also a wonkish alert … get your coffee and settle in for the details), If
Read More →
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
Summaries
Notes: Newsflash ... BARDA have...
Aside: If you've enjoyed the...
Dear All,See also this related...
Dear All (and with thanks...
Dear All (Wonkish alert! Coffee-up!),Today...